Achieving an MMR (BCR::ABL1 ≤ 0.1%) within 12 months predicts a CML-specific survival close to 100%, as disease progression is uncommon once this level of cytoreduction has been achieved. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.